Smokers with Parkinson’s disease have a lower risk of death from neurological problems, but higher risk of dying from smoking-related complications, according to a study by researchers in Korea. The scientists reviewed data from about 28,000 patients, comprising current and ex-smokers, and those who had never smoked. While smokers more commonly died from lung cancer and other cancers, neurological failure was less common among that group. The study suggested that there might be some neuroprotective properties conferred by some ingredients in cigarettes.

According to the World Health Organization, smoking is the leading cause of preventable deaths worldwide, responsible for over 8 million fatalities each year. But what if smoking isn’t all bad? Recent studies have found that there may be some neurological benefits associated with smoking, particularly for individuals with Parkinson’s disease. Researchers have observed a correlation between smoking and a lower risk of developing Parkinson’s, as well as improved dopamine uptake and reduced motor symptoms in those already diagnosed with the disease. In this article, we will explore these neurological benefits seen with smoking in Parkinson’s study and examine what further research may be needed to fully understand this relationship.


Parkinson’s disease patients who smoke cigarettes are less likely to die of neurological problems than non-smokers, according to a study conducted by scientists in Korea. However, the study also found that smokers with Parkinson’s are at a higher risk of death due to related complications, such as lung cancer. The study analysed data for 1,535 people with Parkinson’s who were active smokers, 4,653 patients who were former smokers and 21,880 patients who had never smoked. Over an average follow-up period of more than five years, 8,663 deaths were recorded. There was no significant difference in rates of all-cause mortality risk among the three groups, while the intensity of smoking also did not show a significant association with mortality risk. Other research has consistently shown that people who smoke cigarettes are less likely than non-smokers to develop Parkinson’s disease; one possible explanation is that nicotine or other chemicals in cigarettes may offer protection against the neurodegenerative disease. The authors of the Parkinson’s study concluded that the potential benefits of smoking cigarettes in Parkinson’s do not outweigh the substantial health risks of smoking. However, they added that “further studies are warranted to determine the specific ingredients of cigarettes that are relevant to their neuroprotective effects.”


In conclusion, the link between smoking and neurological benefits in patients with Parkinson’s disease is a complex and intriguing one. While smoking is not a recommended method of managing symptoms of Parkinson’s disease due to its harmful effects on overall health, this study sheds light on the potential role of nicotine in managing the disease. Further research is needed to understand the underlying mechanisms and to explore safer and more effective ways of utilizing nicotine for patients with Parkinson’s disease.